An integrated approach to diagnosing early manifestations of anthracycline-induced cardiovascular toxicity. A literature review
https://doi.org/10.15829/1728-8800-2026-4354
EDN: NCGRKP
Abstract
The emerging problem of cardiovascular toxicity associated with antitumor therapy raises the question of timely diagnosis of its early manifestations. To address this issue, a literature review was conducted on an integrated approach to diagnosing early manifestations of cardiovascular toxicity induced by anthracycline antibiotics, including genetic marker testing, coronary computed tomography angiography (CCTA), and cardiac magnetic resonance imaging.
About the Authors
A. K. Efimova
P. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
2nd Botkinsky proezd, 3, Moscow, 125284
N. A. Rubtsova
P. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
2nd Botkinsky proezd, 3, Moscow, 125284
V. I. Potievskaya
P. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
2nd Botkinsky proezd, 3, Moscow, 125284
K. V. Gallinger
P. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
2nd Botkinsky proezd, 3, Moscow, 125284
References
1. Kanorskii SG, Pavlovets VP. Codiotoxicity of anthracyclines and the possibilities of its correction. South Russian Journal of Therapeutic Practice. 2023;4(3):7-14. (In Russ.) doi:10.21886/2712-8156-2023-4-3-7-14.
2. Gendlin GE, Emelina EI, Nikitin IG, et al. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines. Russian Journal of Cardiology. 2017;(3):145-54. (In Russ.) doi:10.15829/1560-4071-2017-3-145-154.
3. Plokhova EV, Sorokin AV, Staferov AV, et al. Methods of diagnosis in cardio-oncology. Journal of Clinical Practice. 2018;9(1):50-62. (In Russ.) doi:10.17816/clinpract09150-62.
4. Vicenya MV, Ageev FT, Orlova RV, et al. Cardiovascular toxicity. Malignant tumors. 2023;13(3s2-2):83-107. (In Russ.) doi:10.18027/2224-5057-2023-13-3s2-2-83-107. EDN: LZUHIK.
5. Lisitskaya MV, Mershina EA, Larina OM, et al. New applications of cardiac computed tomography for evaluation of myocardial ischemia. Medical Visualization. 2022;26(1):70-7. (In Russ.) doi:10.24835/1607-0763-983.
6. Liu D, Ma Z, Di S, et al. AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. Free Radic Biol Med. 2018;129:59-72. doi:10.1016/j.freeradbi-omed.2018.08.032.
7. Vicenya MV, Ageev FT, Gilyarov MYu, et al. Guidelines for the correction of cardiovascular toxicity of antitumor drug therapy. Malignant tumors. 2022;12(3S2-2):78-100. (In Russ.) Вdoi:10.18027/2224-5057-2022-12-3s2-78-100.
8. Matyash MG, Kravchuk TL, Vysotskaya VV, et al. Anthracyclineinduced cardiotoxicity: mechanisms of development and clinical manifestations. Siberian Journal Of Oncology. 2008;6:66-75. (In Russ.)
9. Balmagambetova S, Tlegenova Zh, Zholdin B, et al. Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol. Diagnostics. 2022;12(11):2714. doi:10.3390/diagnostics12112714.
10. Posch F, Niedrist T, Glantschnig T, et al. Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer. Front Cardiovasc. Med. 2022;9:933428. doi:10.3389/fcvm.2022.933428.
11. Sinitsky MYu, Tsepokina AV, Khutornaya MV, et al. Genetic basis of anthracyclines cardiotoxicity: Literature review. Acta biomedica scientifica. 2021;6(4):27-38. (In Russ.) doi:10.29413/ABS.2021-6.4.3.
12. McGowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1): 63-75. doi:10.1007/s10557-016-6711-0.
13. Tlegenova Zh, Zholdin B, Gendlin G, et al. The troponin prognostic capability in diagnosing cardiotoxicity during chemotherapy with anthracyclines and monoclonal antibodies in breast cancer patients. Science and Healthcare. 2021;23(5):132-48. (In Russ.) doi:10.34689/SH.2021.23.5.016.
14. Levina VD, Poltavskaya MG, Chomakhidze PSh, et al. Highsensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity. Russian Journal of Cardiology. 2022;27(11):5210. (In Russ.) doi:10.15829/1560-4071-2022-5210. EDN: FQWYGM.
15. Kit OI, Gvaldin DYu, Omelchuk EP, et al. Сurrent views on predictors and biomarkers of early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer (review of literature). Klinicheskaya Laboratornaya Diagnostika (Russian Clinical Laboratory Diagnostics). 2020;65(3):141-8. (In Russ.) doi:10.18821/0869-2084-2020-65-3-141-148.
16. Pavo N, Raderer M, Hülsmann M, et al. Cardiovascular biomarkers in patients with cancer and their association with allcause mortality. Heart. 2015;101(23):1874-80. doi:10.1136/heartjnl-2015-307848.
17. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin chem. 2005;51(8):1405-10. doi:10.1373/clinchem.2005.050153.
18. Chaulin AM, Duplyakov DV. Increased natriuretic peptides not associated with heart failure. Russian Journal of Cardiology. 2020;25(S4):4140. (In Russ.) doi:10.15829/1560-40712020-4140.
19. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;23(10):e333-e465. doi:10.1093/eurheartj/ehac244.
20. Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat genet. 2015;47(9):1079-84. doi:10.1038/ng.3374.
21. Visscher H, Ross CJ, Rassekh SR, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children. Pediatr Blood Cancer. 2013;60(8):1375-81. doi:10.1002/pbc.24505.
22. Wang X, Sun CL, Quiñones-Lombraña A, et al. CELF4 variant and anthracycline-related cardiomyopathy: a children’s oncology group genome-wide association study. J Clin Oncol. 2016;34(8): 863-70. doi:10.1200/JCO.2015.63.4550.
23. Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2020;2(4):539-52. doi:10.1016/j.jaccao.2020.09.006.
24. Belenkov YuN, Ilgisonis IS, Khabarova NV, Kirichenko YuYu. Modern Instrumental Methods of Diagnostics and Risk Assessment of Developing Antitumor Therapy Cardiovasculotoxicity. Kardiologiia. 2024;64(8):3-12. (In Russ.) doi:10.18087/cardio.2024.8.n2753.
25. Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:7784. doi:10.1016/j.jacc.2012.09.035.
26. Levina VD, Poltavskaya MG, Chomakhidze PSh, et al. The role of left ventricle global longitudinal srain in prediction of chemotherapy-induced cardiotoxicity in breast cancer patients treated by low and moderate cumulative doses of anthracyclines. Medical alphabet. 2022;(33):19-26. (In Russ.) doi:10.33667/2078-5631-2022-33-19-26.
27. Prus YA, Sergienko IV, Kukharchuk VV, et al. Cardiotoxicity induced by chemotherapy and radiotherapy. Atherosclerosis and dyslipidemias. 2017;(3):56-72. (In Russ.) EDN: YZFRHL.
28. Chistyakova MV, Goncharova EV. Early diagnosis of cardiotoxic complications of chemotherapy: the possibility of radiation research methods. Kardiologiia. 2018;58(12S):11-7. (In Russ.) Чистякова М. В., Гончарова Е. В. Ранняя диагностика кардиотоксических осложнений химиотерапии: возможности лучевых методов исследования. Кардиология. 2018;58(12S):11-7. doi:10.18087/cardio.2512.
29. Chazova IE, Ageev FT, Aksenova AV, et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian Heart Journal. 2022;(1):6-79. (In Russ.) doi:10.38109/2225-1685-2022-1-6-79.
30. Silin AYu, Lesnyak VN. Magnetic resonance imaging in clinical practice. Clinical Practice. 2013;1(13):67-71. (In Russ.) doi:10.17816/clinpract4167-71.
31. Butorova EA, Stukalova OV. Case report: role of cardiac MRI in the diagnosis of myocarditis. Eurasian heart journal. 2023;(3):90-4. (In Russ.) doi:10.38109/2225-1685-2023-3-90-94.
32. Pituskin E, Haykowsky M, Mackey JR, et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumabmediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC cancer. 2011;11(1):1-8. doi:10.1186/1471-2407-11-318.
33. Favreau-Lessard AJ, Sawyer DB, Francis SA. Anthracycline cardiomyopathy: the plot gets thinner. Circ Heart Fail. 2018;11(7): e005194. doi:10.1161/CIRCHEARTFAILURE.118.005194.
34. Ignatieva ES, Ryzhkova DV, Mitrofanova LB, et al. Magnetic resonance imaging of the heart in diagnostics of various types of myocarditis. Russian Journal of Cardiology. 2017;(2):30-8. (In Russ.) doi:10.15829/1560-4071-2017-2-30-38.
35. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):315876. doi:10.1016/j.jacc.2018.09.072.
36. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291-300. doi:10.1056/NEJMoa1415516.
37. Khasanova KA, Abramyan MA, Bedin AV. Potential of Transthoracic Echocardiography and Cardiac CT in Pulmonary Arteries Assessment in Children With Pulmonary Atresia With Ventricular Septal Defect. Innovative Medicine of Kuban. 2024; (1):28-36. (In Russ.) doi:10.35401/2541-9897-2024-9-1-26-36.
38. Layoun ME, Yang EH, Herrmann J, et al. Applications of cardiac computed tomography in the cardio-oncology population. Curr Treat Options Oncol. 2019;20:1-12. doi:10.1007/s11864-0190645-2.
39. Vasyuk YuA, Gendlin GE, Emelina EI, et al. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardioljgy. 2021;26(9):4703. (In Russ.) doi:10.15829/1560-4071-2021-4703.
40. Camilli M, Cardinale DM, Pedrotti P, et al. Report from the Cardio-Oncology Symposium at the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Annual Congress. 2022. Future Cardiol. 2023;19(11):519-22. doi:10.2217/fca-2022-0063.
What is already known about the subject?
- The problem of timely detection of anthracycline-induced cardiovascular toxicity is a pressing concern for cardio-oncology specialists.
- The ongoing issue of the occurrence of negative effects of antitumor therapy in cancer patients requires the use of novel diagnostic methods.
What might this study add?
- Modern diagnostic methods allow for a comprehensive approach to identifying manifestations of cardiovascular toxicity, including laboratory (determining the level of cardiac and genetic markers) and radiological diagnostics.
- Among diagnostic radiology methods for the cardiovascular system, coronary computed tomography angiography and cardiac magnetic resonance imaging proven their effectiveness.
Review
For citations:
Efimova A.K., Rubtsova N.A., Potievskaya V.I., Gallinger K.V. An integrated approach to diagnosing early manifestations of anthracycline-induced cardiovascular toxicity. A literature review. Cardiovascular Therapy and Prevention. 2026;25(2):4354. (In Russ.) https://doi.org/10.15829/1728-8800-2026-4354. EDN: NCGRKP
Views:
180
JATS XML
Email this article 
